A Low Postoperative Nonstimulated Serum Thyroglobulin Level Does Not Exclude the Presence of Radioactive Iodine Avid Metastatic Foci in Intermediate-Risk Differentiated Thyroid Cancer Patients

Thyroid ◽  
2013 ◽  
Vol 23 (4) ◽  
pp. 436-442 ◽  
Author(s):  
Eyal Robenshtok ◽  
Ravinder K. Grewal ◽  
Stephanie Fish ◽  
Mona Sabra ◽  
R. Michael Tuttle
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Intermediate Risk ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Level

scholarly journals Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients

2013 ◽  
Vol 169 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Maria Grazia Castagna ◽  
Gabriele Cevenini ◽  
Alexandra Theodoropoulou ◽  
Fabio Maino ◽  
Silvia Memmo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Recurrent Disease ◽  
Intermediate Risk ◽  
Persistent Disease ◽  
Thyroid Ablation ◽  
The Impact

BackgroundIn differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no evidences are provided regarding the optimal radioactive iodine (RAI) activity to be administered for post-surgical thyroid ablation.MethodsThis study aimed to evaluate the impact of RAI activities on the outcome of 225 DTC patients classified as intermediate risk, treated with low (1110–1850 MBq) or high RAI activities (≥3700 MBq).ResultsSix to 18 months after ablation, remission was observed in 60.0% of patients treated with low and in 60.0% of those treated with high RAI activities, biochemical disease was found in 18.8% of patients treated with low and in 14.3% of patients treated with high RAI activities, metastatic disease was found in 21.2% of patients treated with low and in 25.7% of patients treated with high RAI activities (P=0.56). At the last follow-up (low activities, median 4.2 years; high activities, median 6.9 years), remission was observed in 76.5% of patients treated with low and in 72.1% of patients treated with high RAI activities, persistent disease was observed in 18.8% of patients treated with low and in 23.5% of patients treated with high RAI activities, recurrent disease was 2.4% in patients treated with low and 2.1% in patients treated with high RAI activities, deaths occurred in 2.4% of patients treated with low and in 2.1% of patients treated with high RAI activities (P=0.87).ConclusionOur study provides the first evidence that in DTC patients at intermediate risk, high RAI activities at ablation have no major advantage over low activities.

Clinico-social factors to choose radioactive iodine dose in differentiated thyroid cancer patients

2018 ◽  
Vol 39 (4) ◽  
pp. 283-289 ◽  
Author(s):  
Zeenat Jabin ◽  
Seong Young Kwon ◽  
Hee-Seung Bom ◽  
Yansong Lin ◽  
Ke Yang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Social Factors ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Iodine Dose
Sign in / Sign up

Export Citation Format

Share Document